| __timestamp | Dr. Reddy's Laboratories Limited | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 38783000000 | 50829000 |
| Thursday, January 1, 2015 | 42585000000 | 57305000 |
| Friday, January 1, 2016 | 45702000000 | 116145000 |
| Sunday, January 1, 2017 | 46372000000 | 159362000 |
| Monday, January 1, 2018 | 46910000000 | 206366000 |
| Tuesday, January 1, 2019 | 48890000000 | 228244000 |
| Wednesday, January 1, 2020 | 50129000000 | 293355000 |
| Friday, January 1, 2021 | 54559000000 | 401715000 |
| Saturday, January 1, 2022 | 62081000000 | 459856000 |
| Sunday, January 1, 2023 | 105931000000 | 542705000 |
| Monday, January 1, 2024 | 77201000000 |
In pursuit of knowledge
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Dr. Reddy's Laboratories Limited and Exelixis, Inc. offer a fascinating study in contrasts. Over the past decade, Dr. Reddy's has consistently maintained higher SG&A expenses, peaking at approximately 106 billion in 2023, a staggering 1,900% more than Exelixis's 542 million in the same year. This trend reflects Dr. Reddy's expansive global operations and strategic investments. Meanwhile, Exelixis, with its leaner structure, has shown a steady increase in SG&A, growing nearly tenfold since 2014. This growth aligns with its focused R&D efforts and market expansion. The data from 2024 is incomplete, highlighting the dynamic nature of financial management. As these companies evolve, their SG&A strategies will continue to shape their competitive edge in the pharmaceutical industry.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Comparing SG&A Expenses: Biogen Inc. vs Dr. Reddy's Laboratories Limited Trends and Insights
Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs Jazz Pharmaceuticals plc
Cost Management Insights: SG&A Expenses for Dr. Reddy's Laboratories Limited and Xenon Pharmaceuticals Inc.
Dr. Reddy's Laboratories Limited and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Dr. Reddy's Laboratories Limited and Taro Pharmaceutical Industries Ltd.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and CRISPR Therapeutics AG
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.